Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,387,7523,DB00285,Venlafaxine
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,99.2,7524,DB00285,Venlafaxine
higher,26460073,recoveries,Calibration curves in spiked plasma (recoveries higher than 80%) were linear over the concentration range 150-5000 ng/mL for both VX and O-DVX.,Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26460073/),%,80,11133,DB00285,Venlafaxine
,26460073,limit of detection (LOD),"The limit of detection (LOD) was found to be as low as 30 ng/mL and 21 ng/mL for O-DVX and VX, respectively.",Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26460073/),[ng] / [ml],30,11134,DB00285,Venlafaxine
,26460073,limit of detection (LOD),"The limit of detection (LOD) was found to be as low as 30 ng/mL and 21 ng/mL for O-DVX and VX, respectively.",Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26460073/),[ng] / [ml],21,11135,DB00285,Venlafaxine
,18840027,half-life of development,The half-life of development and regression of tolerance was estimated to be 30 minutes for the amplitude and 40 minutes for the recovery time.,Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840027/),min,30,21502,DB00285,Venlafaxine
,22615601,flow rate,"Chromatographic separation was achieved with a ChromolithTM Performance RP-18e 100 mm×4.6 mm column equipped with a Fluorescence detectore (λ(ex) 200 nm/λ(em) 300 nm) The mobile phase of methanol:water (35:65, v/v) adjusted to pH 2.5 by phosphoric acid was passed through the column in an isocratic mode at flow rate of 2 ml/min.",Development and validation of a rapid HPLC- fluorescence method for simultaneous determination of venlafaxine and its major metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615601/),[ml] / [min],2,25655,DB00285,Venlafaxine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,16.4,26950,DB00285,Venlafaxine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,12.3,26951,DB00285,Venlafaxine
,25069798,Cmax,"Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121.83 ng/mL [90% CI, 111.80-132.75]).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],121.83,30557,DB00285,Venlafaxine
,25069798,AUC0-τ,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],98.71,30558,DB00285,Venlafaxine
,25069798,Cmax,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],101.44,30559,DB00285,Venlafaxine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],96.54,30560,DB00285,Venlafaxine
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],106.39,30561,DB00285,Venlafaxine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],89.67,30562,DB00285,Venlafaxine
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],106.32,30563,DB00285,Venlafaxine
,32974907,AUC ratio,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),,2.83,39446,DB00285,Venlafaxine
,32974907,AUC0-∞,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],526,39447,DB00285,Venlafaxine
,32974907,AUC0-∞,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],195,39448,DB00285,Venlafaxine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],1971,39449,DB00285,Venlafaxine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],2226,39450,DB00285,Venlafaxine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],199,39451,DB00285,Venlafaxine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],151,39452,DB00285,Venlafaxine
,7992822,elimination half-lives,"The selective serotonin reuptake inhibitors (SSRIs)--paroxetine, sertraline, and fluvoxamine--have elimination half-lives of 15-26 hours.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,15-26,43464,DB00285,Venlafaxine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-6,43465,DB00285,Venlafaxine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-16,43466,DB00285,Venlafaxine
,7992822,half-lives,"Venlafaxine and nefazodone have short half-lives, 2-5 hours, and are dosed > or = 2 times daily.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,2-5,43467,DB00285,Venlafaxine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00285,Venlafaxine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00285,Venlafaxine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00285,Venlafaxine
,22345864,bioavailability,The bioavailability of VEN was 11.6%.,Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345864/),%,11.6,60117,DB00285,Venlafaxine
,22345864,percent AUC ratios,"The percent AUC ratios of ODV to VEN were 18% and 39% following intravenous and intragastric administration, respectively.",Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345864/),%,18,60118,DB00285,Venlafaxine
,22345864,percent AUC ratios,"The percent AUC ratios of ODV to VEN were 18% and 39% following intravenous and intragastric administration, respectively.",Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345864/),%,39,60119,DB00285,Venlafaxine
,26331791,plasma concentrations,"IL-6 plasma concentrations varied from 0.4 to 12.9 pg/mL (mean, 2.1 pg/mL) in healthy volunteers and from 0.4 to 29.3 pg/mL (mean, 4.2 pg/mL) in psoriatic patients.",Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26331791/),[pg] / [ml],2.1,63801,DB00285,Venlafaxine
,26331791,plasma concentrations,"IL-6 plasma concentrations varied from 0.4 to 12.9 pg/mL (mean, 2.1 pg/mL) in healthy volunteers and from 0.4 to 29.3 pg/mL (mean, 4.2 pg/mL) in psoriatic patients.",Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26331791/),[pg] / [ml],4.2,63802,DB00285,Venlafaxine
,20133212,flow rate,The separation was carried out on an ACQUITY UPLC BEH C(18) column with 10 mmol/L ammonium acetate and methanol as the mobile phase at a flow rate of 0.30 mL/min.,Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133212/),[ml] / [min],0.30,83099,DB00285,Venlafaxine
,19517423,flow-rate,"The HPLC separation of the analytes was performed on a Zorbax SB-C(18), 50 x 4.6 mm, 5 microm column, using a isocratic elution program using a mobile phase consisting of HPLC-grade methanol: 5 mm ammonium acetate (80:20 v/v) at a flow-rate of 1.0 mL/min with a total runtime of 3.0 min.",Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517423/),[ml] / [min],1.0,85413,DB00285,Venlafaxine
,19517423,total runtime,"The HPLC separation of the analytes was performed on a Zorbax SB-C(18), 50 x 4.6 mm, 5 microm column, using a isocratic elution program using a mobile phase consisting of HPLC-grade methanol: 5 mm ammonium acetate (80:20 v/v) at a flow-rate of 1.0 mL/min with a total runtime of 3.0 min.",Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517423/),min,3.0,85414,DB00285,Venlafaxine
,8888087,apparent clearance,"For O-desmethylvenlafaxine, single doses had a significantly lower apparent clearance in the elderly (0.29 vs 0.38 L/hr/kg), longer half-life (13.2 vs 10.3 hrs), and 14% greater steady-state half-life.",Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888087/),[l] / [h·kg],0.29,87353,DB00285,Venlafaxine
,8888087,apparent clearance,"For O-desmethylvenlafaxine, single doses had a significantly lower apparent clearance in the elderly (0.29 vs 0.38 L/hr/kg), longer half-life (13.2 vs 10.3 hrs), and 14% greater steady-state half-life.",Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888087/),[l] / [h·kg],0.38,87354,DB00285,Venlafaxine
,8888087,half-life,"For O-desmethylvenlafaxine, single doses had a significantly lower apparent clearance in the elderly (0.29 vs 0.38 L/hr/kg), longer half-life (13.2 vs 10.3 hrs), and 14% greater steady-state half-life.",Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888087/),h,13.2,87355,DB00285,Venlafaxine
,8888087,half-life,"For O-desmethylvenlafaxine, single doses had a significantly lower apparent clearance in the elderly (0.29 vs 0.38 L/hr/kg), longer half-life (13.2 vs 10.3 hrs), and 14% greater steady-state half-life.",Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888087/),h,10.3,87356,DB00285,Venlafaxine
no less,28685967,extraction recovery,"The accuracy was in the range of 85-110%, and the extraction recovery was no less than 50%.",Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),%,50,94976,DB00285,Venlafaxine
,28685967,Cmax,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[mg] / [l],0.069,94977,DB00285,Venlafaxine
,28685967,AUC0→∞,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[h·mg] / [l],0.291,94978,DB00285,Venlafaxine
,28685967,Cmax,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[mg] / [l],0.046,94979,DB00285,Venlafaxine
,28685967,AUC0→∞,Both values of Cmax (0.069 mg/L) and AUC0→∞ (0.291 mg h/L) in group B were statistically greater than that of Cmax (0.046 mg/L) and AUC0→∞ (0.181 mg·h/L) in group A (P < 0.05).,Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685967/),[h·mg] / [l],0.181,94980,DB00285,Venlafaxine
,9505987,relative bioavailabilities,"AUC ratios indicated that the relative bioavailabilities of the parent drug, and formulation of metabolite were approximately 98% and 92%, respectively, for the tablet versus the solution.",Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505987/),%,98,95581,DB00285,Venlafaxine
,9505987,relative bioavailabilities,"AUC ratios indicated that the relative bioavailabilities of the parent drug, and formulation of metabolite were approximately 98% and 92%, respectively, for the tablet versus the solution.",Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505987/),%,92,95582,DB00285,Venlafaxine
,15866490,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (250 mmx4.6 mm, 5 microm, Germany) column, using water (formic acid 0.6 per thousand, ammonium acetate: 30 mmol/l)-acetonitrile (35:65, v/v) as mobile phase, with a flow-rate of 0.85 ml/min.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ml] / [min],0.85,96981,DB00285,Venlafaxine
above,15866490,extraction recoveries,The average extraction recoveries for all the four analytes were above 73.2%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,73.2,96982,DB00285,Venlafaxine
higher,15866490,recoveries,The methodology recoveries were higher than 95.0%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,95.0,96983,DB00285,Venlafaxine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.5,96984,DB00285,Venlafaxine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.3,96985,DB00285,Venlafaxine
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.1,96986,DB00285,Venlafaxine
,17230450,flow rate,"The mobile phase was methanol-water containing 10 mmol/L ammonium acetate, pH 7.9 adjusted with aqueous ammonia (80:20, v/v) at the flow rate of 1.0 mL/min.",Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230450/),[ml] / [min],1.0,97411,DB00285,Venlafaxine
,17230450,Relative bioavailability,Relative bioavailability was 103.4 +/- 14.1%.,Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230450/),%,103.4,97412,DB00285,Venlafaxine
,9521568,absolute recovery,The absolute recovery averaged 74% for venlafaxine and 67% for oxydesmethylvenlafaxine.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),%,74,102558,DB00285,Venlafaxine
,9521568,absolute recovery,The absolute recovery averaged 74% for venlafaxine and 67% for oxydesmethylvenlafaxine.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),%,67,102559,DB00285,Venlafaxine
,9521568,sensitivity,The sensitivity was 0.5 ng for both the analytes.,"Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521568/),ng,0.5,102560,DB00285,Venlafaxine
,31571835,Cmax,"The Cmax of the venlafaxine group (control group) and the combination group (experimental group) were (2267.26±252.89) ng/mL and (1542.64±190.73) ng/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],2267.26,113293,DB00285,Venlafaxine
,31571835,Cmax,"The Cmax of the venlafaxine group (control group) and the combination group (experimental group) were (2267.26±252.89) ng/mL and (1542.64±190.73) ng/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],1542.64,113294,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The AUC(0-∞) of the two groups were (13,934.79±3609.23) ng·h/mL and (8001.91±2167.58) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],"13,934.79",113295,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The AUC(0-∞) of the two groups were (13,934.79±3609.23) ng·h/mL and (8001.91±2167.58) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],8001.91,113296,DB00285,Venlafaxine
,31571835,Cmax,"The ODV Cmax of the two groups were (2253.80±215.81) ng/mL and (2721.37±118.20) ng/mL, and AUC(0-∞) were (13,974.99±2784.04) ng·h/mL and (17,539.44±1894.29) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],2253.80,113297,DB00285,Venlafaxine
,31571835,Cmax,"The ODV Cmax of the two groups were (2253.80±215.81) ng/mL and (2721.37±118.20) ng/mL, and AUC(0-∞) were (13,974.99±2784.04) ng·h/mL and (17,539.44±1894.29) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],2721.37,113298,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The ODV Cmax of the two groups were (2253.80±215.81) ng/mL and (2721.37±118.20) ng/mL, and AUC(0-∞) were (13,974.99±2784.04) ng·h/mL and (17,539.44±1894.29) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],"13,974.99",113299,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The ODV Cmax of the two groups were (2253.80±215.81) ng/mL and (2721.37±118.20) ng/mL, and AUC(0-∞) were (13,974.99±2784.04) ng·h/mL and (17,539.44±1894.29) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],"17,539.44",113300,DB00285,Venlafaxine
,31571835,Cmax,"The NDV Cmax of the two groups were (50.98±5.76) ng/mL and (58.74±12.33) ng/mL, and AUC(0-∞) were (179.26±34.94) ng·h/mL and (220.68±51.41) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],50.98,113301,DB00285,Venlafaxine
,31571835,Cmax,"The NDV Cmax of the two groups were (50.98±5.76) ng/mL and (58.74±12.33) ng/mL, and AUC(0-∞) were (179.26±34.94) ng·h/mL and (220.68±51.41) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[ng] / [ml],58.74,113302,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The NDV Cmax of the two groups were (50.98±5.76) ng/mL and (58.74±12.33) ng/mL, and AUC(0-∞) were (179.26±34.94) ng·h/mL and (220.68±51.41) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],179.26,113303,DB00285,Venlafaxine
,31571835,AUC(0-∞),"The NDV Cmax of the two groups were (50.98±5.76) ng/mL and (58.74±12.33) ng/mL, and AUC(0-∞) were (179.26±34.94) ng·h/mL and (220.68±51.41) ng·h/mL, respectively.",Effect Of Chinese Herb Danzhi Xiaoyao Pills On Pharmacokinetics Of Venlafaxine In Beagles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31571835/),[h·ng] / [ml],220.68,113304,DB00285,Venlafaxine
,9549664,absolute bioavailability,The absolute bioavailability of venlafaxine was between 40% and 45% and was similar for both the CF and XR formulations.,Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549664/),%,40,113441,DB00285,Venlafaxine
,9549664,absolute bioavailability,The absolute bioavailability of venlafaxine was between 40% and 45% and was similar for both the CF and XR formulations.,Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549664/),%,45,113442,DB00285,Venlafaxine
,19607765,milk/plasma ratio,The mean milk/plasma ratio was 275.3% (95% CI = 144.8% to 405.7%).,Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19607765/),%,275.3,120989,DB00285,Venlafaxine
,10780263,oral clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],100,130145,DB00285,Venlafaxine
,10780263,oral clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],17,130146,DB00285,Venlafaxine
,10780263,renal clearance,"In extensive metabolizers, quinidine decreased venlafaxine oral clearance from 100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P < 0.05) without any effects on renal clearance (4 +/- 1 l/h during venlafaxine alone and 4 +/- 1 l/h during venlafaxine plus quinidine).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],4,130147,DB00285,Venlafaxine
,10780263,metabolic clearances,"In these individuals, the sequential metabolism of venlafaxine to O-desmethylvenlafaxine and to N,O-didesmethylvenlafaxine was inhibited by quinidine coadministration so that metabolic clearances to O-desmethylated metabolites decreased from 43 +/- 32 l/h to 2 +/- 1 l/h (P < 0.05).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],43,130148,DB00285,Venlafaxine
,10780263,metabolic clearances,"In these individuals, the sequential metabolism of venlafaxine to O-desmethylvenlafaxine and to N,O-didesmethylvenlafaxine was inhibited by quinidine coadministration so that metabolic clearances to O-desmethylated metabolites decreased from 43 +/- 32 l/h to 2 +/- 1 l/h (P < 0.05).",Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780263/),[l] / [h],2,130149,DB00285,Venlafaxine
,20532709,f(1),"The calculated values of f(1) and f(2) were 4.131 and 79.356, respectively; indicating that the release profile of the optimized PEO layered tablet formulation is comparable to that of the target release model.",Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532709/),,4.131,135571,DB00285,Venlafaxine
,20532709,f(2),"The calculated values of f(1) and f(2) were 4.131 and 79.356, respectively; indicating that the release profile of the optimized PEO layered tablet formulation is comparable to that of the target release model.",Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20532709/),,79.356,135572,DB00285,Venlafaxine
,21321974,flow rate,"The mobile phase was methanol-water containing 30 mmol/L ammonium acetate, pH 3.3 adjusted with aqueous ammonia (8:92, v/v) at the flow rate 1.0 mL/min.",Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321974/),[ml] / [min],1.0,139300,DB00285,Venlafaxine
,21321974,m,A tandem mass spectrometer with an electrospray interface was operated in the multiple reaction monitoring mode to detect the selected ions pair at m/z 278.0 → 120.8 for venlafaxine enantiomers and m/z 294.8 → 266.7 for estazolanm (internal standard).,Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321974/),,278.0,139301,DB00285,Venlafaxine
,21321974,m,A tandem mass spectrometer with an electrospray interface was operated in the multiple reaction monitoring mode to detect the selected ions pair at m/z 278.0 → 120.8 for venlafaxine enantiomers and m/z 294.8 → 266.7 for estazolanm (internal standard).,Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321974/),,120.8,139302,DB00285,Venlafaxine
,21321974,m,A tandem mass spectrometer with an electrospray interface was operated in the multiple reaction monitoring mode to detect the selected ions pair at m/z 278.0 → 120.8 for venlafaxine enantiomers and m/z 294.8 → 266.7 for estazolanm (internal standard).,Development and validation of a HPLC-MS/MS method for the determination of venlafaxine enantiomers and application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21321974/),,294.8,139303,DB00285,Venlafaxine
,12472987,elimination half-life,"Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h.",Alternative venlafaxine kinetics in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472987/),h,15.3,162006,DB00285,Venlafaxine
,28547577,concentration,"The initial plasma pramipexole concentration was 34.2 ng/mL (therapeutic range 0.2 to 7 ng/mL), 9 h post-overdose.","Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),[ng] / [ml],34.2,162674,DB00285,Venlafaxine
,28547577,elimination half-life,Concentration time data fitted a one-compartment model with an estimated elimination half-life of 18 h.,"Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),h,18,162675,DB00285,Venlafaxine
,8852394,renal clearance,Lithium significantly reduced the renal clearance of venlafaxine from 0.053 to 0.027 L/h/kg.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.053,167009,DB00285,Venlafaxine
,8852394,renal clearance,Lithium significantly reduced the renal clearance of venlafaxine from 0.053 to 0.027 L/h/kg.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.027,167010,DB00285,Venlafaxine
,8852394,Total clearance,Total clearance (0.026 L/h/kg) and steady-state volume of distribution (0.71 L/kg) of lithium were not affected by administration of venlafaxine.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.026,167011,DB00285,Venlafaxine
,8852394,steady-state volume of distribution,Total clearance (0.026 L/h/kg) and steady-state volume of distribution (0.71 L/kg) of lithium were not affected by administration of venlafaxine.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [kg],0.71,167012,DB00285,Venlafaxine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],734,173027,DB00285,Venlafaxine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],630,173028,DB00285,Venlafaxine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],894,173029,DB00285,Venlafaxine
,28845898,areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ),"The areas under the serum concentration-time curves from 0-24 hours (AUC0-24 ) for venlafaxine (mean ± SD 734 ± 602 vs 630 ± 553 ng·hr/ml, p=0.22) and ODV (mean ± SD 894 ± 899 vs 1083 ± 972 ng·hr/ml, p=0.07) were similar before and after RYGB.",Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845898/),[h·ng] / [ml],1083,173030,DB00285,Venlafaxine
,7650232,oral clearance (CL/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[ml] / [h·kg],24,174662,DB00285,Venlafaxine
,7650232,oral clearance (CL/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[ml] / [h·kg],26,174663,DB00285,Venlafaxine
,7650232,volume of distribution (Vz/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[l] / [kg],0.85,174664,DB00285,Venlafaxine
,7650232,volume of distribution (Vz/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[l] / [kg],0.99,174665,DB00285,Venlafaxine
,7650232,AUC,"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[h·ng] / [ml],5973,174666,DB00285,Venlafaxine
,7650232,AUC,"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[h·ng] / [ml],5008,174667,DB00285,Venlafaxine
,7650232,Critical flicker fusion,Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments.,Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),hz,37.85,174668,DB00285,Venlafaxine
,7650232,Critical flicker fusion,Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments.,Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),hz,37.09,174669,DB00285,Venlafaxine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],40,175115,DB00285,Venlafaxine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],37,175116,DB00285,Venlafaxine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],22,175117,DB00285,Venlafaxine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],55,175118,DB00285,Venlafaxine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],33,175119,DB00285,Venlafaxine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],43,175120,DB00285,Venlafaxine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],48,175121,DB00285,Venlafaxine
,21656534,resolution factor,"The chromatographic separation of the analytes was achieved on a Zorbax Eclipse XDB C(18) (150 × 4.6 mm, 5 µm) analytical column using isocratic mobile phase consisting of 20 mm ammonium acetate-methanol (10:90, v/v), with a resolution factor of 3.5.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),,3.5,182922,DB00285,Venlafaxine
,21656534,process efficiency,"The matrix effect was assessed by post-column infusion and the mean process efficiency was 96.08 and 94.40% for BUP and HBUP, respectively.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),%,96.08,182923,DB00285,Venlafaxine
,21656534,process efficiency,"The matrix effect was assessed by post-column infusion and the mean process efficiency was 96.08 and 94.40% for BUP and HBUP, respectively.","Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656534/),%,94.40,182924,DB00285,Venlafaxine
,31094902,meta,"The metabolite to parent ratio, ODV/VEN, was significantly lower in the VTRIM group (1.15 vs. 2.37, P = 0.012).",Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094902/),,1.15,202287,DB00285,Venlafaxine
,31094902,meta,"The metabolite to parent ratio, ODV/VEN, was significantly lower in the VTRIM group (1.15 vs. 2.37, P = 0.012).",Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094902/),,2.37,202288,DB00285,Venlafaxine
,12185556,meta,"ODV/V metabolite formation ratios for the (+) and (-) enantiomers did not significantly differ from each other (median values 2.85 and 2.37, respectively).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.85,204849,DB00285,Venlafaxine
,12185556,meta,"ODV/V metabolite formation ratios for the (+) and (-) enantiomers did not significantly differ from each other (median values 2.85 and 2.37, respectively).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.37,204850,DB00285,Venlafaxine
,12185556,formation ratios,"ODV/V metabolite formation ratios for the (+) and (-) enantiomers did not significantly differ from each other (median values 2.85 and 2.37, respectively).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.85,204851,DB00285,Venlafaxine
,12185556,formation ratios,"ODV/V metabolite formation ratios for the (+) and (-) enantiomers did not significantly differ from each other (median values 2.85 and 2.37, respectively).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.37,204852,DB00285,Venlafaxine
,12185556,O,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,1.42,204853,DB00285,Venlafaxine
,12185556,O,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,5.08,204854,DB00285,Venlafaxine
,12185556,O,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.36,204855,DB00285,Venlafaxine
,12185556,O,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,3.27,204856,DB00285,Venlafaxine
,12185556,V/V ratio,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,1.42,204857,DB00285,Venlafaxine
,12185556,V/V ratio,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,5.08,204858,DB00285,Venlafaxine
,12185556,V/V ratio,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,2.36,204859,DB00285,Venlafaxine
,12185556,V/V ratio,"When compared with males, females displayed a significantly lower ODV/V ratio for the (-) enantiomer (median values 1.42 vs 5.08 on day 14, P<0.05) but not for the (+) enantiomer (median values 2.36 vs 3.27, n.s.).",Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185556/),,3.27,204860,DB00285,Venlafaxine
,19653973,C(max),"After ingestion of venlafaxine, the C(max) values were 36 +/- 6 ng/mL and 52 +/- 8 ng/mL in the brand-name and generic groups, respectively.",Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653973/),[ng] / [ml],36,205895,DB00285,Venlafaxine
,19653973,C(max),"After ingestion of venlafaxine, the C(max) values were 36 +/- 6 ng/mL and 52 +/- 8 ng/mL in the brand-name and generic groups, respectively.",Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653973/),[ng] / [ml],52,205896,DB00285,Venlafaxine
,22203515,C(max),Formulation F5 showed the C(max) of 24.19 ± 0.72 ng/ml by buccal route of administration and 17.98 ± 1.15 ng/ml by oral route of administration.,"Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: in vivo, in vitro evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203515/),[ng] / [ml],24.19,207489,DB00285,Venlafaxine
,22203515,C(max),Formulation F5 showed the C(max) of 24.19 ± 0.72 ng/ml by buccal route of administration and 17.98 ± 1.15 ng/ml by oral route of administration.,"Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: in vivo, in vitro evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203515/),[ng] / [ml],17.98,207490,DB00285,Venlafaxine
,22203515,bioavailability,The bioavailability of F5 by buccal route was 54.44% and that of by oral route was 39.60%.,"Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: in vivo, in vitro evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203515/),%,54.44,207491,DB00285,Venlafaxine
,22203515,bioavailability,The bioavailability of F5 by buccal route was 54.44% and that of by oral route was 39.60%.,"Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: in vivo, in vitro evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22203515/),%,39.60,207492,DB00285,Venlafaxine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],173,219079,DB00285,Venlafaxine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],20,219080,DB00285,Venlafaxine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],73,219081,DB00285,Venlafaxine
,12544511,oral clearance,"The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],37,219082,DB00285,Venlafaxine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],4,219083,DB00285,Venlafaxine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],5,219084,DB00285,Venlafaxine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],4,219085,DB00285,Venlafaxine
,12544511,renal clearance,"In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],3,219086,DB00285,Venlafaxine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],127,219087,DB00285,Venlafaxine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],1,219088,DB00285,Venlafaxine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],47,219089,DB00285,Venlafaxine
,12544511,partial metabolic clearance,"The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05].",Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544511/),[l] / [h],7,219090,DB00285,Venlafaxine
,1487561,Steady-state elimination half-life,Steady-state elimination half-life was 3 to 4 hours for venlafaxine and 10 hours for O-desmethylvenlafaxine; both were independent of dose.,Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),h,3 to 4,223708,DB00285,Venlafaxine
,1487561,Steady-state elimination half-life,Steady-state elimination half-life was 3 to 4 hours for venlafaxine and 10 hours for O-desmethylvenlafaxine; both were independent of dose.,Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),h,10,223709,DB00285,Venlafaxine
,1487561,oral-dose clearance,"Venlafaxine had a high oral-dose clearance, ranging from 0.58 to 2.63 L/hr/kg across doses with the lowest mean clearance, 0.98 L/hr/kg, at the highest dose.",Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),[l] / [h·kg],0.58 to 2.63,223710,DB00285,Venlafaxine
,1487561,clearance,"Venlafaxine had a high oral-dose clearance, ranging from 0.58 to 2.63 L/hr/kg across doses with the lowest mean clearance, 0.98 L/hr/kg, at the highest dose.",Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),[l] / [h·kg],0.98,223711,DB00285,Venlafaxine
,1487561,apparent clearance,"The apparent clearance of O-desmethylvenlafaxine was lower than venlafaxine, ranging from 0.21 to 0.66 L/hr/kg, and the lowest mean clearance, 0.33 L/hr/kg, occurred at the lowest dose.",Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),[l] / [h·kg],0.21 to 0.66,223712,DB00285,Venlafaxine
,1487561,clearance,"The apparent clearance of O-desmethylvenlafaxine was lower than venlafaxine, ranging from 0.21 to 0.66 L/hr/kg, and the lowest mean clearance, 0.33 L/hr/kg, occurred at the lowest dose.",Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487561/),[l] / [h·kg],0.33,223713,DB00285,Venlafaxine
,25491375,flow rate,The flow rate was 1.2 mL/min.,The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),[ml] / [min],1.2,224818,DB00285,Venlafaxine
,25491375,retention times,"The retention times for OLZ and the IS were 0.78 and 1.04 min, respectively.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),min,0.78,224819,DB00285,Venlafaxine
,25491375,retention times,"The retention times for OLZ and the IS were 0.78 and 1.04 min, respectively.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),min,1.04,224820,DB00285,Venlafaxine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,313.1,224821,DB00285,Venlafaxine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,256.1,224822,DB00285,Venlafaxine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,278.1,224823,DB00285,Venlafaxine
>,25491375,m/z,"Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively).",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),,260.2,224824,DB00285,Venlafaxine
,25491375,recovery,"3. No significant matrix effects were observed on OLZ and the IS retention times, and the mean recovery of OLZ was 90.08%.",The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25491375/),%,90.08,224825,DB00285,Venlafaxine
,26202346,IC50,"Furthermore, apigenin showed inhibitory effect on human and rat microsomes and the IC50 of apigenin was 58.37 and 25.73 μmol/l, respectively.",Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202346/),[μM] / [l],58.37,224954,DB00285,Venlafaxine
,26202346,IC50,"Furthermore, apigenin showed inhibitory effect on human and rat microsomes and the IC50 of apigenin was 58.37 and 25.73 μmol/l, respectively.",Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202346/),[μM] / [l],25.73,224955,DB00285,Venlafaxine
,9321527,ka,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),1/[h],1.31,230084,DB00285,Venlafaxine
,9321527,VVEN,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),l,252,230085,DB00285,Venlafaxine
,9321527,CLint,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),[l] / [h],65.8,230086,DB00285,Venlafaxine
,9321527,RL (,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),,29.6,230087,DB00285,Venlafaxine
,9321527,liver:plasma partition coefficient,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),,29.6,230088,DB00285,Venlafaxine
,9321527,VODV,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),l,181,230089,DB00285,Venlafaxine
,9321527,CLODV,"A good fit of the model to observed data was demonstrated, generating estimates for the following parameters: ka (1.31 +/- 0.009 hr-1), VVEN (252 +/- 87.6 liters), CLint (65.8 +/- 39.7 liters/hr), RL (liver:plasma partition coefficient, 29.6 +/- 18. 3), VODV (181 +/- 84.1 liters), and CLODV (23.5 +/- 12.5 liters/hr).",Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321527/),[l] / [h],23.5,230090,DB00285,Venlafaxine
,17222591,flow-rate,"The HPLC separation of the analytes was performed on a Thermo BDS HYPERSIL C18 (250 mm x 4.6 mm, 5 microm, USA) column, using a gradient elution program with solvents constituted of water (ammonium acetate: 30 mmol/l, formic acid 2.6 mmol/l and trifluoroacetic acid 0.13 mmol/l) and acetonitrile (60:40, V/V) at a flow-rate of 1.0 ml/min.",High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),[ml] / [min],1.0,230654,DB00285,Venlafaxine
above,17222591,extraction recoveries,The average extraction recoveries for all the four analytes were above 77%.,High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),%,77,230655,DB00285,Venlafaxine
higher,17222591,recoveries,The methodology recoveries were higher than 91%.,High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),%,91,230656,DB00285,Venlafaxine
,17222591,limits of detection,"The limits of detection were 0.4, 0.2, 0.3, and 0.2 ng/ml for VEN, ODV, NDV and DDV, respectively.",High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),[ng] / [ml],0.4,230657,DB00285,Venlafaxine
,17222591,limits of detection,"The limits of detection were 0.4, 0.2, 0.3, and 0.2 ng/ml for VEN, ODV, NDV and DDV, respectively.",High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),[ng] / [ml],0.2,230658,DB00285,Venlafaxine
,17222591,limits of detection,"The limits of detection were 0.4, 0.2, 0.3, and 0.2 ng/ml for VEN, ODV, NDV and DDV, respectively.",High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17222591/),[ng] / [ml],0.3,230659,DB00285,Venlafaxine
,8059535,Absolute bioavailability,"3. Absolute bioavailability was low in rat and rhesus monkey (12.6 and 6.5%, respectively) and moderate in dog (59.8%).",Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059535/),%,12.6,233952,DB00285,Venlafaxine
,8059535,Absolute bioavailability,"3. Absolute bioavailability was low in rat and rhesus monkey (12.6 and 6.5%, respectively) and moderate in dog (59.8%).",Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059535/),%,6.5,233953,DB00285,Venlafaxine
,8059535,Absolute bioavailability,"3. Absolute bioavailability was low in rat and rhesus monkey (12.6 and 6.5%, respectively) and moderate in dog (59.8%).",Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059535/),%,59.8,233954,DB00285,Venlafaxine
,8059535,elimination half-life,"Other species differences were seen, including an elimination half-life of venlafaxine that was longer in dog and rhesus monkey (2-4 h) than in rodent (around 1 h).",Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059535/),h,2-4,233955,DB00285,Venlafaxine
,8059535,elimination half-life,"Other species differences were seen, including an elimination half-life of venlafaxine that was longer in dog and rhesus monkey (2-4 h) than in rodent (around 1 h).",Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059535/),h,1,233956,DB00285,Venlafaxine
,33204067,IC50,We observed that vonoprazan could significantly decrease the amount of O-desmethylvenlafaxine (IC50 = 5.544 μM).,In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33204067/),μM,5.544,236264,DB00285,Venlafaxine
,18675598,lambda(em),"Fluorescence detection was used (lambda(ex) 276 nm, lambda(em) 598 nm).",Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675598/),,598,239218,DB00285,Venlafaxine
less,18675598,limit of detection (LOD),The limit of detection (LOD) was less than 2 ng mL(-1) (S/N=3) and the limit of quantification (LOQ) was less than 10 ng mL(-1) (S/N=10).,Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675598/),[ng] / [ml],2,239219,DB00285,Venlafaxine
,18675598,S/N,The limit of detection (LOD) was less than 2 ng mL(-1) (S/N=3) and the limit of quantification (LOQ) was less than 10 ng mL(-1) (S/N=10).,Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675598/),,3,239220,DB00285,Venlafaxine
less,18675598,limit of quantification (LOQ),The limit of detection (LOD) was less than 2 ng mL(-1) (S/N=3) and the limit of quantification (LOQ) was less than 10 ng mL(-1) (S/N=10).,Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675598/),[ng] / [ml],10,239221,DB00285,Venlafaxine
,18675598,S/N,The limit of detection (LOD) was less than 2 ng mL(-1) (S/N=3) and the limit of quantification (LOQ) was less than 10 ng mL(-1) (S/N=10).,Determination of venlafaxine in human plasma by high-performance liquid chromatography using cloud-point extraction and spectrofluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675598/),,10,239222,DB00285,Venlafaxine
,29403857,flow rate,"The UPLC separation of the analytes was performed on ACQUITY UPLC® BEH Shield RP18 (1.7 µm, 100 mm×2.1 mm) column, using isocratic elution with mobile phase constituted of water (containing 2 mM ammonium acetate): acetonitrile (20:80, v/v) at a flow rate of 0.3 mL/min.",Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403857/),[ml] / [min],0.3,241983,DB00285,Venlafaxine
,29403857,m/,"The precursor to product ion transitions monitored for VEN, ODV and Venlafaxine d6 were m/z 278.3→121.08, 264.2→107.1 and 284.4→121.0, respectively.",Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403857/),,278.3,241984,DB00285,Venlafaxine
,29403857,m/,"The precursor to product ion transitions monitored for VEN, ODV and Venlafaxine d6 were m/z 278.3→121.08, 264.2→107.1 and 284.4→121.0, respectively.",Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403857/),,121.08,241985,DB00285,Venlafaxine
,29403857,m/,"The precursor to product ion transitions monitored for VEN, ODV and Venlafaxine d6 were m/z 278.3→121.08, 264.2→107.1 and 284.4→121.0, respectively.",Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403857/),,264.2,241986,DB00285,Venlafaxine
,29403857,m/,"The precursor to product ion transitions monitored for VEN, ODV and Venlafaxine d6 were m/z 278.3→121.08, 264.2→107.1 and 284.4→121.0, respectively.",Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403857/),,284.4,241987,DB00285,Venlafaxine
,17940637,elimination half-life,It has a mean elimination half-life of 6.3 hours.,"Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17940637/),h,6.3,244022,DB00285,Venlafaxine
,29704798,flow rate,"The analytes were separated on an Agilent SB-Phenyl (50 mm × 4.6 mm, 3.5 μm) column using a binary gradient of 0.1% formic acid in water versus 0.1% formic acid in acetonitrile at a flow rate of 0.8 mL/min.",Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29704798/),[ml] / [min],0.8,257843,DB00285,Venlafaxine
,25567760,entrapment,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),%,74.9,259877,DB00285,Venlafaxine
,25567760,mean size,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),nm,186.3,259878,DB00285,Venlafaxine
,25567760,zata potential,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),mv,-22.8,259879,DB00285,Venlafaxine
,11270914,oral clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],104,260600,DB00285,Venlafaxine
,11270914,oral clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],43,260601,DB00285,Venlafaxine
,11270914,renal clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],4,260602,DB00285,Venlafaxine
,11270914,renal clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],4,260603,DB00285,Venlafaxine
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264140,DB00285,Venlafaxine
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,98,264141,DB00285,Venlafaxine
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264142,DB00285,Venlafaxine
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,87,264143,DB00285,Venlafaxine
,20954808,mucoadhesion,"Formulation F4 showed the maximum mucoadhesion 89.37 ± 1.35%, 92.10 ± 1.37% incorporation efficiency, highest swelling index 0.770 ± 1.23.","In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),%,89.37,267144,DB00285,Venlafaxine
,20954808,incorporation efficiency,"Formulation F4 showed the maximum mucoadhesion 89.37 ± 1.35%, 92.10 ± 1.37% incorporation efficiency, highest swelling index 0.770 ± 1.23.","In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),%,92.10,267145,DB00285,Venlafaxine
,20954808,swelling index,"Formulation F4 showed the maximum mucoadhesion 89.37 ± 1.35%, 92.10 ± 1.37% incorporation efficiency, highest swelling index 0.770 ± 1.23.","In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),,0.770,267146,DB00285,Venlafaxine
,20954808,bioavailability,F4 showed a marked increase in the bioavailability after buccal administration (51.86 ± 3.95) as compared to oral route (39.60 ± 6.16).,"In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),,51.86,267147,DB00285,Venlafaxine
,20954808,bioavailability,F4 showed a marked increase in the bioavailability after buccal administration (51.86 ± 3.95) as compared to oral route (39.60 ± 6.16).,"In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),,39.60,267148,DB00285,Venlafaxine
,20954808,time to reach maximum plasma concentration,Also it took less time to reach maximum plasma concentration of 21.38 ± 1.05 ng/ml as compared to oral solution where it required 180 min to reach maximum plasma concentration of 17.98 ± 1.14.,"In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),[ng] / [ml],21.38,267149,DB00285,Venlafaxine
,20954808,maximum plasma concentration,Also it took less time to reach maximum plasma concentration of 21.38 ± 1.05 ng/ml as compared to oral solution where it required 180 min to reach maximum plasma concentration of 17.98 ± 1.14.,"In vivo, in vitro evaluation of linseed mucilage based buccal mucoadhesive microspheres of venlafaxine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954808/),,17.98,267150,DB00285,Venlafaxine
